The non–invasive liquid biopsy is less painful and easier to perform than tissue biopsies which track patient progress.
The test can predict how patients respond to treatment by measuring tumour markers in the blood.
Clinicians hope to drive more precise available treatments to patients and stop drugs that are unlikely to work as sooner.